Narala Sagar, Komanduri Neeraja, Nyavanandi Dinesh, Youssef Ahmed Adel Ali, Mandati Preethi, Alzahrani Abdullah, Kolimi Praveen, Narala Nagarjuna, Repka Michael A
Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS, 38677.
Department of Pharmaceutical Technology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
J Drug Deliv Sci Technol. 2023 Apr;82. doi: 10.1016/j.jddst.2023.104384. Epub 2023 Mar 21.
Aqueous solubility is one of the key parameters for achieving the desired drug concentration in systemic circulation for better therapeutic outcomes. Carbamazepine (CBZ) is practically insoluble in water, is a BCS class II drug, and exhibits dissolution-dependent oral bioavailability. This study explored a novel application of hot-melt extrusion in the manufacture and development of a thermodynamically stable solid crystal suspension (SCS) to improve the solubility and dissolution rate of CBZ. The SCSs were prepared using sugar alcohols, such as mannitol or xylitol, as crystalline carriers. The drug-sugar blend was processed by hot melt extrusion up to 40 % (w/w) drug loading. The extruded SCS was evaluated for drug content, saturation solubility, differential scanning calorimetry (DSC), Fourier-transform infrared (FTIR) spectroscopy, powder X-ray diffraction (PXRD), scanning electron microscopy (SEM), release, and stability studies. The physicochemical characterization revealed the highly crystalline existence of pure drug, pure carriers, and extruded SCS. FTIR analysis did not reveal any physical or chemical incompatibilities between the drug and sugar alcohols and showed a homogeneous CBZ distribution within respective crystalline carriers. The SEM micrographs of the solidified SCS revealed the presence of approximately 100 μm crystalline agglomerates. dissolution and solubility studies showed that the CBZ dissolution rate and solubility were improved significantly from both crystalline carriers for all tested drug loads. The SCSs showed no significant changes in drug content, release profiles, and thermal characteristics over 3 months of storage at accelerated stability conditions (40±2°C/75±5% RH). As a result, it can be inferred that the SCS strategy can be employed as a contemporary alternative technique to improve the dissolution rate of BCS class II drugs via HME technology.
水溶性是在体循环中达到所需药物浓度以获得更好治疗效果的关键参数之一。卡马西平(CBZ)几乎不溶于水,属于BCS II类药物,其口服生物利用度取决于溶出度。本研究探索了热熔挤出在制造和开发热力学稳定的固体晶体混悬液(SCS)中的新应用,以提高CBZ的溶解度和溶出速率。使用甘露醇或木糖醇等糖醇作为结晶载体来制备SCS。将药物 - 糖混合物通过热熔挤出处理,药物载量高达40%(w/w)。对挤出的SCS进行药物含量、饱和溶解度、差示扫描量热法(DSC)、傅里叶变换红外(FTIR)光谱、粉末X射线衍射(PXRD)、扫描电子显微镜(SEM)、释放和稳定性研究。物理化学表征揭示了纯药物、纯载体和挤出的SCS的高度结晶状态。FTIR分析未发现药物与糖醇之间存在任何物理或化学不相容性,并显示CBZ在各自的结晶载体内分布均匀。固化SCS的SEM显微照片显示存在约100μm的结晶聚集体。溶出度和溶解度研究表明,对于所有测试的药物载量,来自两种结晶载体的CBZ溶出速率和溶解度均显著提高。在加速稳定性条件(40±2°C/75±5%RH)下储存3个月期间,SCS的药物含量、释放曲线和热特性均无显著变化。因此,可以推断SCS策略可作为一种当代替代技术,通过热熔挤出技术提高BCS II类药物的溶出速率。